Axa
MRNA icon

Axa’s Moderna MRNA Stock Holding History

Axa’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$398K Sell
7,826
-3,079
-28% -$144K 0.16% 64
2025
Q4 		$322K Buy
+10,905
New +$296K 0.15% 67
2025
Q3 		– Sell
-48,000
Closed -$1.32M – 682
2025
Q2 		$1.32M Sell
48,000
-119,024
-71% -$3.13M ﹤0.01% 837
2025
Q1 		$4.74M Sell
167,024
-2,158
-1% -$76.6K 0.02% 557
2024
Q4 		$7.03M Sell
169,182
-38,456
-19% -$1.84M 0.02% 455
2024
Q3 		$13.9M Buy
207,638
+2,649
+1% +$243K 0.04% 344
2024
Q2 		$24.3M Buy
204,989
+1,947
+1% +$246K 0.07% 238
2024
Q1 		$21.6M Sell
203,042
-271,510
-57% -$27.4M 0.06% 264
2023
Q4 		$47.2M Sell
474,552
-128,488
-21% -$10.8M 0.15% 148
2023
Q3 		$62.3M Buy
603,040
+109,999
+22% +$12.3M 0.22% 109
2023
Q2 		$59.9M Buy
493,041
+113,540
+30% +$15.1M 0.2% 118
2023
Q1 		$58.3M Sell
379,501
-147,412
-28% -$24.3M 0.2% 126
2022
Q4 		$94.6M Buy
526,913
+291,235
+124% +$47.6M 0.34% 74
2022
Q3 		$27.9M Buy
235,678
+110,303
+88% +$16.7M 0.11% 211
2022
Q2 		$17.9M Sell
125,375
-2,224
-2% -$318K 0.07% 318
2022
Q1 		$22M Buy
127,599
+34,472
+37% +$5.8M 0.06% 343
2021
Q4 		$23.7M Sell
93,127
-37,470
-29% -$11M 0.06% 330
2021
Q3 		$50.3M Sell
130,597
-22,023
-14% -$8.12M 0.14% 180
2021
Q2 		$35.9M Sell
152,620
-17,418
-10% -$3.11M 0.1% 233
2021
Q1 		$22.3M Buy
170,038
+3,160
+2% +$458K 0.07% 327
2020
Q4 		$17.4M Buy
166,878
+3,790
+2% +$383K 0.05% 363
2020
Q3 		$11.5M Buy
163,088
+1,513
+0.9% +$105K 0.04% 410
2020
Q2 		$10.4M Buy
161,575
+3,181
+2% +$174K 0.04% 419
2020
Q1 		$4.74M Buy
+158,394
New +$3.64M 0.02% 530

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Axa's MRNA Position: Q1 2026 in Review

Axa reduced its Moderna (MRNA) stake by 28% in Q1 2026, selling an estimated $144K and leaving 7,826 shares worth $398K. The position accounts for 0.16% of the portfolio, ranked #64.

Axa first reported a position in MRNA in Q1 2020 and has held it in 24 quarters since. The position peaked at $94.6M in Q4 2022. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Axa held 7,826 shares of Moderna worth $398K as of Q1 2026.
  • Axa sold 3,079 Moderna shares in Q1 2026, an estimated $144K.
  • Moderna made up 0.16% of Axa's portfolio in Q1 2026, its #64 holding.
  • Axa first reported a position in Moderna in Q1 2020 and has held it in 24 quarters since.
  • Axa's Moderna position peaked at $94.6M in Q4 2022.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Axa's 13F filing for Q1 2026, filed 15 May 2026.